First patient dosed in the phase 2a part of Medivir’s study with fostrox in combination with Lenvima®

Medivir AB announced that the first patient with hepatocellular carcinoma has started treatment in phase 2a with the candidate drug fostroxacitabine bralpamide in combination with Lenvima®.